Chengdu's HitGen to Collaborate with Global Blood Therapeutics

HitGen Ltd, a Chengdu CRO specializing in drug discovery, formed a research collaboration with Global Blood Therapeutics of the US, a clinical-stage biopharma focused on therapeutics for blood-based disorders. HitGen will provide biology, chemistry, and screening on an undisclosed novel GBT target. GBT's lead molecule is a clinical-stage drug candidate that treats the underlying mechanism of sickle cell disease, which was recently granted Orphan Drug designation in the US. More details.... Stock Symbol: (NSDQ: GBT) Share this with colleagues: // //